InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Scholar Rock Holding Corp

SRRK Clue Score46
United States Fiscal year ends December CIK 0001727196 Results filed 6 Aug 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

50
Insider
Date
Role
Action
Shares
Price
Amount
Srinivas Akkaraju
26 Oct 2026
Director
Buy indirect
97,982
$41.59
$4.08M
Srinivas Akkaraju
26 Oct 2026
Director
Buy indirect
48,988
$41.59
$2.04M
Srinivas Akkaraju
23 Oct 2026
Director
Buy indirect
1,000
$41.82
$41.82K
Srinivas Akkaraju
23 Oct 2026
Director
Buy indirect
500
$41.82
$20.91K
Srinivas Akkaraju
23 Oct 2026
Director
Buy indirect
94,000
$41.31
$3.88M
Srinivas Akkaraju
23 Oct 2026
Director
Buy indirect
47,000
$41.31
$1.94M
Katie Peng
1 Jul 2026
Director
Sold on a plan
21
$54.96
$1.15K
Katie Peng
1 Jul 2026
Director
Sold on a plan
2,437
$54.25
$132.21K
Katie Peng
1 Jul 2026
Director
Sold on a plan
2,988
$53.56
$160.04K
Joshua Reed
1 Jul 2026
Director
Sold on a plan
948
$54.28
$51.46K
Joshua Reed
1 Jul 2026
Director
Sold on a plan
2,105
$53.50
$112.61K
Kristina Burow
1 Jul 2026
Director
Sold on a plan
948
$54.28
$51.46K
Kristina Burow
1 Jul 2026
Director
Sold on a plan
2,105
$53.49
$112.60K
Michael Gilman
1 Jul 2026
Director
Sold on a plan
43
$54.81
$2.36K
Michael Gilman
1 Jul 2026
Director
Sold on a plan
1,155
$54.23
$62.63K
Michael Gilman
1 Jul 2026
Director
Sold on a plan
1,346
$53.54
$72.07K
Jeffrey S. Flier
1 Jul 2026
Director
Sold on a plan
15
$54.88
$823.14
Jeffrey S. Flier
1 Jul 2026
Director
Sold on a plan
1,470
$54.24
$79.73K
Jeffrey S. Flier
1 Jul 2026
Director
Sold on a plan
1,568
$53.53
$83.94K
Kristina Burow
23 Apr 2026
Director
Exercised, kept
18,000
$8.36
$150.48K
Kristina Burow
23 Apr 2026
Director
Exercised, kept
36,000
$9.11
$327.96K
Kristina Burow
23 Apr 2026
Director
Exercised, kept
28,000
$4.75
$133.00K
Kristina Burow
23 Apr 2026
Director
Exercised, kept
7,800
$26.78
$208.88K
David Hallal
16 Apr 2026
Chief Executive Officer
Sell
30,615
$49.57
$1.52M
Vikas Sinha
16 Apr 2026
Chief Financial Officer
Sell
10,410
$49.57
$516.07K
Akshay Vaishnaw
16 Apr 2026
President of R&D
Sell
12,246
$49.57
$607.09K
Keith Woods
16 Apr 2026
Chief Operating Officer
Sell
10,220
$49.57
$506.65K
Mo Qatanani
23 Feb 2026
Chief Scientific Officer
Sold on a plan
200
$48.48
$9.70K
Mo Qatanani
23 Feb 2026
Chief Scientific Officer
Sold on a plan
857
$47.86
$41.01K
Mo Qatanani
23 Feb 2026
Chief Scientific Officer
Sold on a plan
7,427
$46.94
$348.64K
Mo Qatanani
17 Feb 2026
Chief Scientific Officer
Sell
7,989
$46.53
$371.71K
Caryn Parlavecchio
17 Feb 2026
CHRO
Sell
9,035
$46.53
$420.38K
Junlin Ho
17 Feb 2026
General Counsel
Sell
9,580
$46.53
$445.74K
Jing L. Marantz
17 Feb 2026
Chief Medical Officer
Sell
4,157
$46.53
$193.42K
Mo Qatanani
22 Jan 2026
Chief Scientific Officer
Sold on a plan
12,779
$46.85
$598.75K
Mo Qatanani
22 Jan 2026
Chief Scientific Officer
Sold on a plan
2,119
$45.87
$97.19K
Junlin Ho
16 Jan 2026
General Counsel
Sell
8,016
$44.48
$356.53K
Jing L. Marantz
16 Jan 2026
Chief Medical Officer
Sell
5,798
$44.48
$257.88K
Caryn Parlavecchio
16 Jan 2026
CHRO
Sell
6,600
$44.48
$293.55K
Mo Qatanani
16 Jan 2026
Chief Scientific Officer
Sell
8,406
$44.48
$373.88K
Mo Qatanani
14 Jan 2026
Chief Scientific Officer
Sold after exercise
13,112
$45.20
$592.61K
David Hallal
13 Jan 2026
Chief Executive Officer
Sell
57,450
$42.70
$2.45M
Akshay Vaishnaw
13 Jan 2026
President of R&D
Sell
20,438
$42.70
$872.70K
Keith Woods
13 Jan 2026
Chief Operating Officer
Sell
16,746
$42.70
$715.05K
Vikas Sinha
13 Jan 2026
Chief Financial Officer
Sell
16,755
$42.70
$715.44K
Katie Peng
16 Dec 2025
Director
Sold on a plan
280
$44.63
$12.50K
Katie Peng
16 Dec 2025
Director
Sold on a plan
726
$43.88
$31.85K
Srinivas Akkaraju
12 Dec 2025
Director
Exercised, kept indirect
1,064,804
$7.35
$7.83M
Invus Global Management, LLC
11 Dec 2025
10% owner
Exercised, kept
1,575,008
$7.35
$11.58M
Mo Qatanani
4 Dec 2025
Chief Scientific Officer
Sold after exercise
136,462
$45.21
$6.17M

What was left out

Form 4 filings counted 47
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 20
Sales straight out of an exercise 2
Sales at will 16
Transactions with no price 0
Shares from compensation/vesting 3,410,382
History held since 31 May 2018